TLX
TELIX Pharmaceuticals Ltd
$15.78
▼ -3.19%
Market cap
$5.37B
Turnover
$24,550,953
Last price
$15.78
Day change
-3.19%
Announcements
9
Range, past year
Open 14.36 · Low 8.260 · Now 15.78 · High 29.64
Open TLX in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
TLX momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-10-13.
Momentum quality
38/100
Wyckoff phase
Accumulation1d
Trend stage
Neutral
1 Day
-3.2%
1 Week
+2.4%
1 Month
-3.4%
1 Year
+9.0%
RSI
48
Avg daily range
4.7%
TELIX Pharmaceuticals Ltd scores 38 out of 100 for momentum quality, a reading rated low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Accumulation, where it has been for 1 trading day. The weekly timeframe reads Uptrend, which does not yet agree with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
Points to watch
- Risk rating: High
- Composite downside risk elevated
TLX announcements
Recent price-sensitive releases.
- 2026-09-30 FDA Fast Track for BiPASS Pre Biopsy Prostate Imaging Progress Report
- 2026-09-21 Telix and ITM Join Forces to Create Radiopharma Powerhouse Company Presentation | Progress Report
- 2026-09-14 FDA Approves Telix Brain Cancer Imaging Drug Pixclara Progress Report
- 2026-08-20 Telix HY26 Results Presentation Company Presentation | Half Yearly Report
- 2026-08-20 Telix HY26 Results Announcement Web Cast | Half Yearly Report
- 2026-08-20 Telix HY26 Appendix 4D and Interim Report Half Yearly Report | Half Year Audit Review | Half Year Directors' Statement | Half Year Accounts | Half Year Directors' Report
- 2026-07-21 Q2 2026 Revenue US$247M Strong Momentum Pipeline Progress
More Health Care stocks
Most traded in the same sector.